Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

[1]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[2]  M. Delorenzi,et al.  Systemic and central nervous system metabolic alterations in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[3]  J. Troncoso,et al.  Neurotransmitter Imbalance in the Brain and Alzheimer's Disease Pathology. , 2019, Journal of Alzheimer's disease : JAD.

[4]  K. Blennow,et al.  Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease , 2019, Journal of Neuroinflammation.

[5]  Henrik Zetterberg,et al.  Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau , 2019, Neurobiology of Aging.

[6]  I. Wilson,et al.  Ultrahigh-Performance Liquid Chromatography Tandem Mass Spectrometry with Electrospray Ionization Quantification of Tryptophan Metabolites and Markers of Gut Health in Serum and Plasma—Application to Clinical and Epidemiology Cohorts , 2019, Analytical chemistry.

[7]  T. R. Licht,et al.  Microbial tryptophan catabolites in health and disease , 2018, Nature Communications.

[8]  R. Martins,et al.  Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study , 2018, Scientific Reports.

[9]  E. Green,et al.  The Influence of Nicotinamide on Health and Disease in the Central Nervous System , 2018, International journal of tryptophan research : IJTR.

[10]  V. Salomaa,et al.  Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts , 2018, Alzheimer's & Dementia.

[11]  M. Mattson,et al.  NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency , 2018, Proceedings of the National Academy of Sciences.

[12]  P. Sachdev,et al.  Nicotinamide adenine dinucleotide and its related precursors for the treatment of Alzheimer's disease , 2017, Current opinion in psychiatry.

[13]  Sterling C. Johnson,et al.  Gut microbiome alterations in Alzheimer’s disease , 2017, Scientific Reports.

[14]  J. Ruas,et al.  Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health , 2017, Science.

[15]  Y. An,et al.  Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study , 2017, PLoS medicine.

[16]  Yang Li,et al.  Regulating the balance between the kynurenine and serotonin pathways of tryptophan metabolism , 2017, The FEBS journal.

[17]  Per Magne Ueland,et al.  Kynurenine Pathway Metabolites in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[18]  P. Reddy,et al.  Therapeutics of Neurotransmitters in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[19]  M. M. Parisi,et al.  Quinolinic acid neurotoxicity: Differential roles of astrocytes and microglia via FGF-2-mediated signaling in redox-linked cytoskeletal changes. , 2016, Biochimica et biophysica acta.

[20]  P. Elliott,et al.  Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic Phenotyping. , 2016, Analytical chemistry.

[21]  Y. Sheline,et al.  Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo , 2016, Molecular Neurodegeneration.

[22]  S. Vollset,et al.  Plasma Biomarkers of Inflammation, the Kynurenine Pathway, and Risks of All-Cause, Cancer, and Cardiovascular Disease Mortality , 2016, American journal of epidemiology.

[23]  P. Francis,et al.  Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status , 2016, CNS Drugs.

[24]  M. Hashimoto,et al.  Relationship between Eating Disturbance and Dementia Severity in Patients with Alzheimer’s Disease , 2015, PloS one.

[25]  M. Zou,et al.  Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. , 2015, Frontiers in bioscience.

[26]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[27]  Claire Paquet,et al.  Neuroinflammation and Aβ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation , 2015, Scientific Reports.

[28]  D. Fuchs,et al.  Elevated fecal calprotectin in patients with Alzheimer’s dementia indicates leaky gut , 2015, Journal of Neural Transmission.

[29]  P. Sham,et al.  Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease , 2015, Translational Psychiatry.

[30]  Andrew H. Van Benschoten,et al.  Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. , 2014, Cell host & microbe.

[31]  M. Spraul,et al.  Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. , 2014, Analytical chemistry.

[32]  Douglas B. Kell,et al.  Molecular phenotyping of a UK population: defining the human serum metabolome , 2014, Metabolomics.

[33]  T. Dinan,et al.  Minireview: Gut microbiota: the neglected endocrine organ. , 2014, Molecular endocrinology.

[34]  H. Soininen,et al.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease , 2014, Neurobiology of Aging.

[35]  B. de Strooper,et al.  Regulation of Amyloid Precursor Protein Processing by Serotonin Signaling , 2014, PloS one.

[36]  H. Hampel,et al.  Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[37]  A. Verkhratsky,et al.  The serotonergic system in ageing and Alzheimer's disease , 2012, Progress in Neurobiology.

[38]  R. Schwarcz,et al.  Kynurenic acid and 3-hydroxykynurenine production from d-kynurenine in mice , 2012, Brain Research.

[39]  M. Mintun,et al.  Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans , 2011, Proceedings of the National Academy of Sciences.

[40]  L. Marner,et al.  Cerebral serotonin 4 receptors and amyloid-β in early Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[41]  H. Soininen,et al.  CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study. , 2011, Journal of Alzheimer's disease : JAD.

[42]  D. Pawlak,et al.  Kynurenine and its metabolites in Alzheimer's disease patients. , 2010, Advances in medical sciences.

[43]  B. Brew,et al.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease , 2009, Journal of Neuroinflammation.

[44]  A. Simmons,et al.  AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.

[45]  A. Simmons,et al.  MRI Measures of Alzheimer's Disease and the AddNeuroMed Study , 2009, Annals of the New York Academy of Sciences.

[46]  D. Dougherty,et al.  L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications , 2009, International journal of tryptophan research : IJTR.

[47]  F. LaFerla,et al.  Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau , 2008, The Journal of Neuroscience.

[48]  K. Başar,et al.  Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels , 2007, Psychiatry Research.

[49]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[50]  D. Fuchs,et al.  Monitoring tryptophan metabolism in chronic immune activation. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[51]  M. Garcia-Alloza,et al.  Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease , 2005, Neuropsychologia.

[52]  R. Urso,et al.  Activity of Citalopram on Adenosine and Serotonin Circulating Levels in Depressed Patients , 2005, Journal of clinical psychopharmacology.

[53]  B. Jilma,et al.  Early Effects of Paroxetine on Serotonin Storage, Plasma Levels, and Urinary Excretion: A Randomized, Double-Blind, Placebo-Controlled Trial , 2004, Journal of clinical psychopharmacology.

[54]  B. Brew,et al.  A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.

[55]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[56]  B. Brew,et al.  Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease , 2002, Redox report : communications in free radical research.

[57]  Satoshi Takahashi,et al.  Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia , 1992, Neuroscience Letters.

[58]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .